$1.35 Earnings Per Share Expected for Illumina, Inc. (ILMN) This Quarter

Brokerages predict that Illumina, Inc. (NASDAQ:ILMN) will report earnings of $1.35 per share for the current quarter, Zacks reports. Six analysts have made estimates for Illumina’s earnings. The lowest EPS estimate is $1.32 and the highest is $1.47. Illumina reported earnings per share of $1.44 during the same quarter last year, which suggests a negative year over year growth rate of 6.2%. The company is expected to issue its next earnings report on Tuesday, January 29th.

On average, analysts expect that Illumina will report full-year earnings of $5.75 per share for the current financial year, with EPS estimates ranging from $5.72 to $5.87. For the next fiscal year, analysts forecast that the firm will report earnings of $6.37 per share, with EPS estimates ranging from $6.07 to $6.83. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for Illumina.

Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.26 by $0.26. The firm had revenue of $853.00 million during the quarter, compared to analysts’ expectations of $825.65 million. Illumina had a net margin of 21.09% and a return on equity of 27.10%. The company’s revenue was up 19.5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.11 earnings per share.

ILMN has been the subject of a number of analyst reports. ValuEngine cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 11th. Barclays lifted their target price on shares of Illumina from $350.00 to $370.00 and gave the company an “overweight” rating in a research note on Wednesday, October 24th. BidaskClub upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 1st. Argus set a $372.00 target price on shares of Illumina and gave the company a “buy” rating in a research note on Friday, August 10th. Finally, Cowen lifted their target price on shares of Illumina from $315.00 to $400.00 and gave the company a “positive” rating in a research note on Thursday, September 6th. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $330.94.

In other news, EVP Marc Stapley sold 1,000 shares of Illumina stock in a transaction that occurred on Thursday, December 6th. The shares were sold at an average price of $329.69, for a total value of $329,690.00. Following the transaction, the executive vice president now owns 7,857 shares of the company’s stock, valued at $2,590,374.33. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Francis A. Desouza sold 3,000 shares of Illumina stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $345.90, for a total transaction of $1,037,700.00. Following the completion of the transaction, the insider now directly owns 65,443 shares in the company, valued at approximately $22,636,733.70. The disclosure for this sale can be found here. In the last three months, insiders sold 71,082 shares of company stock worth $23,398,609. Insiders own 0.54% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. Wetherby Asset Management Inc. increased its position in Illumina by 7.1% during the third quarter. Wetherby Asset Management Inc. now owns 2,259 shares of the life sciences company’s stock worth $829,000 after acquiring an additional 149 shares during the period. Cadence Capital Management LLC increased its position in Illumina by 3.6% during the second quarter. Cadence Capital Management LLC now owns 4,702 shares of the life sciences company’s stock worth $1,313,000 after acquiring an additional 162 shares during the period. Stone Ridge Asset Management LLC increased its position in Illumina by 7.1% during the third quarter. Stone Ridge Asset Management LLC now owns 2,557 shares of the life sciences company’s stock worth $939,000 after acquiring an additional 169 shares during the period. Kingfisher Capital LLC increased its position in Illumina by 2.1% during the third quarter. Kingfisher Capital LLC now owns 8,653 shares of the life sciences company’s stock worth $3,176,000 after acquiring an additional 176 shares during the period. Finally, Sumitomo Mitsui Asset Management Company LTD increased its position in Illumina by 1.8% during the second quarter. Sumitomo Mitsui Asset Management Company LTD now owns 10,241 shares of the life sciences company’s stock worth $2,860,000 after acquiring an additional 179 shares during the period. 88.91% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ ILMN traded down $12.91 during trading on Friday, reaching $321.41. The company’s stock had a trading volume of 1,086,450 shares, compared to its average volume of 1,009,090. The company has a quick ratio of 2.24, a current ratio of 2.46 and a debt-to-equity ratio of 0.24. The stock has a market capitalization of $49.15 billion, a PE ratio of 80.35, a price-to-earnings-growth ratio of 2.48 and a beta of 1.09. Illumina has a 1-year low of $207.51 and a 1-year high of $372.61.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Read More: How is inflation measured?

Get a free copy of the Zacks research report on Illumina (ILMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply